Two major regulatory approvals have transformed treatment options for classical Hodgkin lymphoma, a cancer affecting white blood cells called lymphocytes that are part of the immune system. The U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) combined with doxorubicin, vinblastine, and dacarbazine (AVD) for adults and children ages 12 and older with previously untreated advanced disease. Meanwhile, the European Commission approved Opdivo combined with brentuximab vedotin for children as young as 5, adolescents, and young adults up to age 30 with relapsed or refractory disease after one prior treatment. What Makes These New Treatments Different? The U.S. approval represents a significant shift in how doctors treat newly diagnosed advanced Hodgkin lymphoma. The Opdivo-AVD combination demonstrated a 58% reduction in the risk of disease progression or death compared to the previous standard treatment, brentuximab vedotin plus AVD. This means patients receiving the new combination had substantially better outcomes in terms of how long they remained disease-free. The European approval is particularly noteworthy because it offers a chemotherapy-sparing approach for younger patients. The Opdivo and brentuximab vedotin combination achieved high complete metabolic response rates, meaning cancer activity was eliminated or dramatically reduced in most patients. This matters because it reduces exposure to harsh chemotherapy drugs that can cause long-term side effects in children and young adults. What Do the Clinical Trial Results Show? The U.S. approval is based on the SWOG 1826 study, the largest classical Hodgkin lymphoma trial ever conducted in the National Cancer Institute's clinical trials network. The study included nearly 1,000 participants and compared the new Opdivo-AVD combination to the previous standard treatment. After a median follow-up of 36.7 months, the median overall survival had not been reached in either treatment arm, but the Opdivo-AVD group had significantly fewer deaths: 9 deaths (1.8%) compared to 17 deaths (3.4%) in the standard treatment group. The European approval is based on the CheckMate-744 study, a Phase 2 trial that evaluated Opdivo combined with brentuximab vedotin in younger patients with relapsed or refractory disease. The response-adapted regimen allowed most patients to proceed to consolidation therapy while maintaining a manageable safety profile, and responses were durable at follow-up. What Are the Potential Side Effects? Like all immunotherapy treatments, these combinations carry risks that patients and doctors need to discuss carefully. In the SWOG 1826 study, serious adverse reactions occurred in 39% of patients receiving Opdivo-AVD. The most common serious side effects included peripheral neuropathy (nerve damage affecting 41% of patients), neutropenia (low white blood cell count in 7%), fever in 7%, febrile neutropenia (fever with low white blood cells in 6%), and nausea in 6%. Overall, the most frequent side effects were nausea (70%), neutropenia (61%), fatigue (59%), anemia (51%), constipation (49%), low white blood cell count (44%), muscle and bone pain (42%), elevated liver enzymes (41%), vomiting (33%), and mouth sores (30%). Three patients experienced fatal adverse reactions, all from sepsis, representing 0.6% of the treatment group. How to Discuss These Treatment Options With Your Doctor - Ask About Your Specific Situation: These approvals apply to specific patient groups. If you have newly diagnosed Stage III or IV disease, the Opdivo-AVD combination may be an option. If you're under 30 with relapsed or refractory disease, the Opdivo-brentuximab vedotin combination might be relevant. Confirm which approval applies to your diagnosis. - Understand the Survival Benefit: Request specific data about progression-free survival and overall survival for your situation. The 58% reduction in disease progression risk is substantial, but your doctor can explain what this means for your individual prognosis and expected outcomes. - Review Side Effect Management Plans: Since nausea, fatigue, and nerve damage are common, ask your medical team what supportive care options are available. Understanding how side effects will be managed helps you prepare and maintain quality of life during treatment. - Discuss Long-Term Effects: Ask about potential long-term complications, especially if you're a younger patient who may live decades after treatment. Understanding both immediate and delayed side effects helps inform your decision. Dr. Alex Herrera, Chief of the Division of Lymphoma at City of Hope National Medical Center, emphasized the significance of these advances. "In the U.S., the nivolumab-based combination for patients with previously untreated Stage III or IV classical Hodgkin lymphoma demonstrated improved progression-free survival compared with standard of care, BV-AVD," he stated. "The SWOG 1826 study provides data for frontline use of this immunotherapy-based regimen." Alex Herrera, Chief of the Division of Lymphoma at City of Hope National Medical Center "Each new FDA-approved therapy brings renewed hope for patients and their families, and advances like this one signal meaningful progress in improving outcomes for people facing this disease," said Dr. Gwen Nichols, Chief Medical Officer of Blood Cancer United. Dr. Gwen Nichols, Chief Medical Officer of Blood Cancer United Why Do These Approvals Matter Beyond Individual Patients? These regulatory decisions represent a fundamental shift in how doctors approach Hodgkin lymphoma treatment. For decades, chemotherapy-based regimens were the standard, even for newly diagnosed patients. The FDA approval of an immunotherapy-based combination as a first-line treatment signals that the field is moving toward approaches that may offer better outcomes with potentially different side effect profiles. The European approval of a chemotherapy-sparing option for younger patients is particularly significant because it prioritizes long-term quality of life for people who may live 50 or more years after treatment. If you or a loved one has been diagnosed with classical Hodgkin lymphoma, these new treatment options should be part of your conversation with your oncology team. The approvals are recent, so not all treatment centers may have immediate experience with these regimens, but they represent meaningful progress in a disease that has challenged doctors and patients for generations.
